信件：肝病与2019冠状病毒病——并非完美风暴。作者回复
Letter: liver disease and COVID-19-not the perfect storm. Authors' reply".
作者信息
Garrido Isabel, Liberal Rodrigo, Macedo Guilherme
机构信息
Gastroenterology and Hepatology Department, Centro Hospitalar Sao Joao, Porto, Portugal.
World Gastroenterology Organization (WGO) Porto Training Center, Porto, Portugal.
出版信息
Aliment Pharmacol Ther. 2020 Aug;52(3):574-575. doi: 10.1111/apt.15886.
Abstract
This article is linked to Garrido et al and Nathwani et al papers. To view these articles, visit https://doi.org/10.1111/apt.15813 and https://doi.org/10.1111/apt.15872.
摘要
本文与加里多等人以及纳特瓦尼等人的论文相关联。要查看这些文章，请访问https://doi.org/10.1111/apt.15813和https://doi.org/10.1111/apt.15872。
相似文献
1
Letter: liver disease and COVID-19-not the perfect storm. Authors' reply".信件：肝病与2019冠状病毒病——并非完美风暴。作者回复
Aliment Pharmacol Ther. 2020 Aug;52(3):574-575. doi: 10.1111/apt.15886.
2
Letter: elevated liver enzymes and outcomes in COVID Authors' reply.信件：新冠患者中肝酶升高与预后 作者回复
Aliment Pharmacol Ther. 2020 Oct;52(7):1235-1236. doi: 10.1111/apt.16028.
3
Letter: liver involvement and mortality in COVID-19 patients - authors' reply.信函：新冠病毒感染患者的肝脏受累情况及死亡率——作者回复
Aliment Pharmacol Ther. 2020 Oct;52(7):1264-1265. doi: 10.1111/apt.16052.
4
Letter: liver disease and COVID-19-not the perfect storm.信件：肝病与新冠病毒——并非完美风暴
Aliment Pharmacol Ther. 2020 Aug;52(3):572-574. doi: 10.1111/apt.15872.
5
Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors. Authors' reply.信函：肠道炎症、COVID-19与胃肠道ACE2——探索RAS抑制剂。作者回复。
Aliment Pharmacol Ther. 2020 Aug;52(3):571-572. doi: 10.1111/apt.15893. Epub 2020 Jun 25.
6
Letter: unknown denominator and misleading conclusions in Covid-19-authors' reply.信件：关于新冠疫情中未知分母和误导性结论——作者回复
Aliment Pharmacol Ther. 2020 Oct;52(7):1243-1244. doi: 10.1111/apt.16056.
7
Letter: population mortality from COVID-19 and latitude-data from China. Authors' reply.信函：新冠病毒肺炎导致的人群死亡率与纬度——来自中国的数据。作者回复。
Aliment Pharmacol Ther. 2020 Oct;52(7):1261-1262. doi: 10.1111/apt.16058.
8
Letter: gastrointestinal symptoms pre-admission are associated with greater severity of COVID-19-authors' reply.信件：入院前的胃肠道症状与新冠病毒疾病的更严重程度相关——作者回复
Aliment Pharmacol Ther. 2020 Oct;52(7):1231-1232. doi: 10.1111/apt.16045.
9
Letter: low population mortality from COVID-19 in countries south of latitude 35° North supports vitamin D as a factor determining severity. Authors' reply.信件：北纬35°以南国家新冠病毒疾病（COVID-19）的低人口死亡率支持维生素D是决定疾病严重程度的一个因素。作者回复。
Aliment Pharmacol Ther. 2020 Jul;52(2):412-413. doi: 10.1111/apt.15823. Epub 2020 Jun 2.
10
Letter: severe COVID-19 infection and biologic therapies-a cohort study of 7808 patients in France. Authors' reply.
Aliment Pharmacol Ther. 2020 Oct;52(7):1249-1250. doi: 10.1111/apt.16055.
引用本文的文献
1
Decompensated Csirrhosis and COVID 19; Report of Two Cases.失代偿期肝硬化与新型冠状病毒肺炎；两例报告。
Middle East J Dig Dis. 2022 Jan;14(1):136-140. doi: 10.34172/mejdd.2022.267. Epub 2022 Jan 30.
本文引用的文献
1
Letter: liver disease and COVID-19-not the perfect storm.信件：肝病与新冠病毒——并非完美风暴
Aliment Pharmacol Ther. 2020 Aug;52(3):572-574. doi: 10.1111/apt.15872.
2
High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry.患有慢性肝病和肝硬化的患者感染新型冠状病毒的死亡率很高：一项国际登记处的初步结果
J Hepatol. 2020 Sep;73(3):705-708. doi: 10.1016/j.jhep.2020.05.013. Epub 2020 May 21.
3
Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis.肝肾疾病患者感染新型冠状病毒肺炎的预后：一项早期系统评价与Meta分析
Trop Med Infect Dis. 2020 May 15;5(2):80. doi: 10.3390/tropicalmed5020080.
4
The liver in times of COVID-19: What hepatologists should know.COVID-19 时期的肝脏：肝病学家应该了解的知识。
Ann Hepatol. 2020 Jul-Aug;19(4):353-358. doi: 10.1016/j.aohep.2020.05.001. Epub 2020 May 18.
5
Review article: COVID-19 and liver disease-what we know on 1st May 2020.综述文章：2020 年 5 月 1 日的 COVID-19 和肝脏疾病——我们所知道的。
Aliment Pharmacol Ther. 2020 Jul;52(2):267-275. doi: 10.1111/apt.15813. Epub 2020 Jun 2.
6
Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study.美国已有肝病患者中2019冠状病毒病的临床特征与转归：一项多中心研究网络研究
Gastroenterology. 2020 Aug;159(2):768-771.e3. doi: 10.1053/j.gastro.2020.04.064. Epub 2020 May 4.
7
The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care.新冠疫情将对肝硬化治疗质量产生长期影响。
J Hepatol. 2020 Aug;73(2):441-445. doi: 10.1016/j.jhep.2020.04.005. Epub 2020 Apr 13.
Zotero 插件